GlassScriptPhysician profile
Mehras Akhavan
NPI 1497817332
$554.09
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $161 · 2021: $73.27 · 2022: $74.41 · 2024: $20.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.29 | 2019-2021 | |
| Lilly USA, LLC | $79.86 | 2020-2022 | |
| Daiichi Sankyo INC. | $45.11 | 2019 | |
| Amgen INC. | $34.89 | 2019 | |
| Abbvie INC. | $32.37 | 2022 | |
| Assertio Therapeutics, INC. | $22.55 | 2019 | |
| Ibsa Pharma INC. | $22.17 | 2020 | |
| Scilex Pharmaceuticals INC. | $22.03 | 2022 | |
| Glaxosmithkline, LLC. | $21.70 | 2021 | |
| Bioventus LLC | $21.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.78 | 2019 | |
| Redhill Biopharma INC. | $20.56 | 2020 | |
| Forte Bio-Pharma LLC | $20.23 | 2024 | Prolate, Nalocet |
| Vertiflex, INC. | $18.97 | 2019 | |
| Biodelivery Sciences International, INC. | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehras Akhavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.